Health Care • Biotechnology: Commercial Physical & Biological Resarch
$4.37 ▼ -0.09
(-2.02%)
MKT CAP: $26.3M • VOL: 48.0K
52W L $4 52W H $23
ROARABLE / RQD
E • 29/100
PIOTROSKI
2 / 9
ONMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.4M | $643.0K | $1.0M |
| YoY Revenue Growth % | +111.4% | -37.0% | — |
| Gross Profit | -$503.0K | -$281.0K | — |
| Gross Margin % | -37.0% | -43.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.7M | -$9.6M | -$6.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$2.8M | -$10.1M | -$33.8M |
| EBITDA (Normalized) | -$9.7M | -$9.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.5M | -$7.0M | -$4.8M |
| Capital Expenditures (CapEx) | $13.0K | $51.0K | — |
| Free Cash Flow (FCF) | -$7.5M | -$7.0M | -$4.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $585.0K | $172.0K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$3.0M | -$15.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ONMD.